Linked Life Data

7529522

Source:http://linkedlifedata.com/resource/pubmed/id/7529522

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1995-2-16
pubmed:abstractText
The FONICAP group is screening, with randomised phase II studies, the activity of new chemotherapy programmes for advanced non-small-cell lung cancer (NSCLC) looking for regimens with > 30% activity. In the present study, three regimens were tested: MIP (mitomycin 6 mg m-2, ifosfamide 3 g m-2, cisplatinum 80 mg m-2 on day 1 every 28 days); MIP-IFN (MIP and interferon alpha-2b 3 MU s.c. three times a week); and PC (cisplatinum 60 mg m-2 and carboplatin 400 mg m-2 on day 1 every 28 days). Overall 93 chemotherapy-naive patients were enrolled: 23 received MIP, 27 received MIP-IFN and 43 received PC. Eighty per cent of the patients had stage IV and 20% stage IIIb disease (positive pleural effusion or supraclavicular nodes). Response rates were as follows: MIP = 9% (95% CI 1-28%), MIP-IFN = 7% (95% CI 1-24%) and PC = 14% (95% CI 5-28%). The overall median survival was 183 days. Grade III-IV leucopenia was observed in 36% of patients treated with MIP-IFN vs 10% in the other two arms, and thrombocytopenia grade III-IV was reported in nearly 10% of patients overall. In conclusion, (1) all three regimens investigated have poor activity (< 30%); (2) when tested in multicentre randomised phase II trials, MIP displays lower activity than in phase II trials; (3) PC has similar activity to other platinum-containing regimens; (4) randomised phase II studies are a reliable and quick method of determining the anti-tumour activity of novel chemotherapeutic regimens in NSCLC.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-1328881, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-1666469, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-2155066, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-2177346, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-2181152, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-2553879, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-2647285, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-2702835, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-2833402, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-2846024, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-3040245, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-3088219, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-6387060, http://linkedlifedata.com/resource/pubmed/commentcorrection/7529522-8113843
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
71
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
115-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.
pubmed:affiliation
Department of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, V. le Benedetto XY, Genoa, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Clinical Trial, Phase II